{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:21:00Z","timestamp":1791566460662,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08231"],"award-info":[{"award-number":["22K08231"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to assess the clinical utility of serum interferon-lambda 3 (IFN-\u03bb3) as a sequential biomarker for treatment response and disease control in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM)-associated interstitial lung disease (ILD). Serum IFN-\u03bb3 levels were measured in 24 patients with anti-MDA5 antibody-positive DM-ILD at diagnosis and 1\u00a0month after initiating immunosuppressive therapy. Patients were categorized into two groups based on clinical outcomes: a good control group (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200916; survived without relapse for\u2009\u2265\u20091\u00a0year) and a poor control group (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20098; died from ILD progression or relapse within 1\u00a0year). Changes in serum IFN-\u03bb3 levels and differences between groups were analyzed. In the good control group, serum IFN-\u03bb3 levels significantly decreased from 94.6 to 12.7\u00a0pg\/mL (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), whereas no significant change was observed in the poor control group (129.0 to 118.8\u00a0pg\/mL). Furthermore, serum IFN-\u03bb3 levels at 1\u00a0month were significantly lower in the good control group than in the poor control group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004). Serum IFN-\u03bb3 levels may reflect short-term treatment response and could serve as a useful sequential biomarker for assessing disease control in patients with anti-MDA5 antibody-positive DM-ILD.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-37104-x","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T03:15:04Z","timestamp":1769224504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum interferon-\u03bb3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILD"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9211-3173","authenticated-orcid":false,"given":"Yoshihiro","family":"Kitahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-1781","authenticated-orcid":false,"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuki","family":"Fukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Koda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3255-6268","authenticated-orcid":false,"given":"Taisuke","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Yokomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Koshimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Imokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0049-0834","authenticated-orcid":false,"given":"Keita","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-0830","authenticated-orcid":false,"given":"Moriya","family":"Iwaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-5324","authenticated-orcid":false,"given":"Masato","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8075-0597","authenticated-orcid":false,"given":"Yusuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7134-3364","authenticated-orcid":false,"given":"Hideki","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-1543","authenticated-orcid":false,"given":"Hironao","family":"Hozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6154-9791","authenticated-orcid":false,"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0455-4070","authenticated-orcid":false,"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4079-5509","authenticated-orcid":false,"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3187-4264","authenticated-orcid":false,"given":"Noriyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4624-7119","authenticated-orcid":false,"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5300-0504","authenticated-orcid":false,"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"37104_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","volume":"121","author":"H Hozumi","year":"2016","unstructured":"Hozumi, H. et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir. Med. 121, 91\u201399 (2016).","journal-title":"Respir. Med."},{"issue":"7","key":"37104_CR2","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","volume":"57","author":"S Sato","year":"2018","unstructured":"Sato, S. et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: A multicentre cohort of 497 patients. Rheumatology (Oxford) 57(7), 1212\u20131221 (2018).","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"37104_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/medicina57040347","volume":"57","author":"T Fujisawa","year":"2021","unstructured":"Fujisawa, T. Management of myositis-associated interstitial lung disease. Medicina (Kaunas). 57(4), 347 (2021).","journal-title":"Medicina (Kaunas)."},{"issue":"8","key":"37104_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0961203316651748","volume":"25","author":"R Nakashima","year":"2016","unstructured":"Nakashima, R., Hosono, Y. & Mimori, T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus 25(8), 925\u2013933 (2016).","journal-title":"Lupus"},{"issue":"2","key":"37104_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.55563\/clinexprheumatol\/zmn18h","volume":"40","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y. et al. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease. Clin. Exp. Rheumatol. 40(2), 292\u2013297 (2022).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"37104_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.55563\/clinexprheumatol\/df2oc3","volume":"40","author":"Q Yang","year":"2022","unstructured":"Yang, Q. et al. Anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses. Clin. Exp. Rheumatol. 40(2), 304\u2013308 (2022).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"37104_CR7","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono, T. et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 51(9), 1563\u20131570 (2012).","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"37104_CR8","doi-asserted-by":"publisher","first-page":"e20190295","DOI":"10.1084\/jem.20190295","volume":"217","author":"A Broggi","year":"2020","unstructured":"Broggi, A., Granucci, F. & Zanoni, I. Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion. J. Exp. Med. 217(1), e20190295 (2020).","journal-title":"J. Exp. Med."},{"issue":"10","key":"37104_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-019-0182-z","volume":"19","author":"L Ye","year":"2019","unstructured":"Ye, L., Schnepf, D. & Staeheli, P. Interferon-\u03bb orchestrates innate and adaptive mucosal immune responses. Nat. Rev. Immunol. 19(10), 614\u2013625 (2019).","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"37104_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/gene.2008.87","volume":"10","author":"C Dellgren","year":"2009","unstructured":"Dellgren, C., Gad, H. H., Hamming, O. J., Melchjorsen, J. & Hartmann, R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun. 10(2), 125\u2013131 (2009).","journal-title":"Genes Immun."},{"issue":"7","key":"37104_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/RHU.0000000000000581","volume":"23","author":"LM Amezcua-Guerra","year":"2017","unstructured":"Amezcua-Guerra, L. M. et al. Type III interferons in systemic lupus erythematosus: Association between interferon \u03bb3, disease activity, and anti-Ro\/SSA antibodies. J. Clin. Rheumatol. 23(7), 368\u2013375 (2017).","journal-title":"J. Clin. Rheumatol."},{"issue":"1","key":"37104_CR12","doi-asserted-by":"publisher","first-page":"14834","DOI":"10.1038\/s41598-019-50709-9","volume":"9","author":"M Metwally","year":"2019","unstructured":"Metwally, M. et al. IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. Sci. Rep. 9(1), 14834 (2019).","journal-title":"Sci. Rep."},{"issue":"1","key":"37104_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10067-024-07227-5","volume":"44","author":"J Wen","year":"2025","unstructured":"Wen, J. et al. Serum level of IFN-\u03bb is elevated in idiopathic inflammatory myopathies. Clin. Rheumatol. 44(1), 327\u2013340 (2025).","journal-title":"Clin. Rheumatol."},{"issue":"5","key":"37104_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/art.42785","volume":"76","author":"A Fukada","year":"2024","unstructured":"Fukada, A. et al. Prognostic role of interferon-\u03bb3 in anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated interstitial lung disease. Arthritis Rheumatol. 76(5), 796\u2013805 (2024).","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"37104_CR15","doi-asserted-by":"publisher","first-page":"25537","DOI":"10.1038\/s41598-025-10895-1","volume":"15","author":"A Yoshida","year":"2025","unstructured":"Yoshida, A. et al. Dysregulated type I\/III interferon system in circulation from patients with anti-MDA5-positive dermatomyositis. Sci. Rep. 15(1), 25537 (2025).","journal-title":"Sci. Rep."},{"issue":"7","key":"37104_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292(7), 344\u2013347 (1975).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"37104_CR17","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg, I. E. et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann. Rheum. Dis. 76(12), 1955\u20131964 (2017).","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"37104_CR18","doi-asserted-by":"publisher","first-page":"e98824","DOI":"10.1371\/journal.pone.0098824","volume":"9","author":"T Fujisawa","year":"2014","unstructured":"Fujisawa, T. et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS ONE 9(6), e98824 (2014).","journal-title":"PLoS ONE"},{"issue":"5","key":"37104_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1183\/09031936.06.00038806","volume":"28","author":"T Suda","year":"2006","unstructured":"Suda, T. et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur. Respir. J. 28(5), 1005\u20131012 (2006).","journal-title":"Eur. Respir. J."},{"issue":"8","key":"37104_CR20","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3899\/jrheum.180825","volume":"46","author":"T Fujisawa","year":"2019","unstructured":"Fujisawa, T. et al. Clinical significance of serum chitotriosidase level in anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease. J. Rheumatol. 46(8), 935\u2013942 (2019).","journal-title":"J. Rheumatol."},{"key":"37104_CR21","doi-asserted-by":"publisher","first-page":"145145","DOI":"10.1016\/j.gene.2020.145145","volume":"766","author":"M Sugiyama","year":"2021","unstructured":"Sugiyama, M. et al. Serum CCL17 level becomes a predictive marker to distinguish between mild\/moderate and severe\/critical disease in patients with COVID-19. Gene 766, 145145 (2021).","journal-title":"Gene"},{"issue":"8","key":"37104_CR22","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00535-014-1023-2","volume":"50","author":"Y Aoki","year":"2015","unstructured":"Aoki, Y. et al. Association of serum IFN-\u03bb3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. J. Gastroenterol. 50(8), 894\u2013902 (2015).","journal-title":"J. Gastroenterol."},{"issue":"1","key":"37104_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/14397595.2018.1452179","volume":"29","author":"T Gono","year":"2019","unstructured":"Gono, T., Okazaki, Y., Murakami, A. & Kuwana, M. Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody. Mod. Rheumatol. 29(1), 140\u2013145 (2019).","journal-title":"Mod. Rheumatol."},{"issue":"2 Pt 1","key":"37104_CR24","first-page":"646","volume":"161","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 161(2 Pt 1), 646\u2013664 (2000).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"37104_CR25","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu, G. et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 205(9), e18\u2013e47 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"37104_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48(3), 452\u2013458 (2013).","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"37104_CR27","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rmed.2013.01.014","volume":"107","author":"K Tanizawa","year":"2013","unstructured":"Tanizawa, K. et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir. Med. 107(5), 745\u2013752 (2013).","journal-title":"Respir. Med."},{"issue":"1","key":"37104_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13075-018-1683-z","volume":"20","author":"JY Chen","year":"2018","unstructured":"Chen, J. Y. et al. Interferon-\u03bb3\/4 genetic variants and interferon-\u03bb3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese. Arthritis Res. Ther. 20(1), 193 (2018).","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"37104_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tim.2018.08.007","volume":"27","author":"AG Dias Junior","year":"2019","unstructured":"Dias Junior, A. G., Sampaio, N. G. & Rehwinkel, J. A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol. 27(1), 75\u201385 (2019).","journal-title":"Trends Microbiol."},{"issue":"6","key":"37104_CR30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","volume":"140","author":"C Cassius","year":"2020","unstructured":"Cassius, C. et al. MDA5(+) dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript. J. Invest. Dermatol. 140(6), 1276\u20139.e7 (2020).","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"37104_CR31","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/rheumatology\/key386","volume":"58","author":"N Ono","year":"2019","unstructured":"Ono, N. et al. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology (Oxford) 58(5), 786\u2013791 (2019).","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"37104_CR32","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/bjd.16917","volume":"180","author":"SH Zhang","year":"2019","unstructured":"Zhang, S. H. et al. Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis. Br. J. Dermatol. 180(5), 1090\u20131098 (2019).","journal-title":"Br. J. Dermatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37104-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37104-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37104-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:29:47Z","timestamp":1770892187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37104-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37104"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37104-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6134"}}